Devonian Announces the Filing of a New Patent Application Related to Use of Thylakoids as Delivery System for Cannabinoïds and Other Liposoluble Molecules

QUEBEC–(BUSINESS WIRE)–Devonian Health Group Inc. (“Devonian” or the “Corporation“)
(TSXv: GSD), a clinical stage biopharmaceutical corporation, today
announced that the Corporation has filed a patent application for the
use of thylakoids as delivery system for cannabinoids and other
liposoluble molecules for pharmaceutical and cosmetic applications.

The patent application relates to thylakoids and functional derivatives,
as carriers for molecules. More specifically, this invention relates to
a composition comprising functional thylakoids, particularly in specific
formulations that ensure the integrity and functionality of molecules,
particularly liposoluble molecules, that are difficult to formulate, to
increase their bioavailability. The patent covers the extraction of
cannabinoids-containing thylakoids from plant such as Cannabis sativa,
indica or hemp. It also covers the incorporation of liposoluble
molecules, such as cannabinoids, into thylakoids extracted from any
photosynthetic organism.

“The filing of this new patent is another pivotal component of our broad
strategy of expanding our already list of patents. Importantly, this
filing is timely as we look to demonstrate the potential broad
application of our technology. Furthermore, this new patent aligns to
our pharmaceutical cannabinoids-based drug development program.” said
Dr. André P. Boulet, President & CEO of Devonian.

About Devonian

Devonian Health Group Inc. is a late stage biopharmaceutical corporation
with novel therapeutic approaches to targeting unmet medical needs.
Devonian’s core strategy is to develop prescription botanical drugs from
plant materials and algae for the treatment of inflammatory-autoimmune
diseases including but not limited to ulcerative colitis and atopic
dermatitis. Based on a foundation of over 15 years of research,
Devonian’s focus is further supported by a US-FDA set of regulatory
guidelines favouring a more efficient drug development pathway for
prescription botanical drug products over those of traditional
prescription medicines. Devonian is also involved in the development of
high-value cosmeceutical products leveraging the same proprietary
approach employed with their pharmaceutical offerings. Devonian Health
Group Inc. was incorporated in 2013 and is headquartered in Québec,
Canada where it owns a state-of-the art extraction facility with full
traceability ‘from the seed to the pill’. Acquired in 2018, Altius
Healthcare Inc., its commercial division, brings opportunities for
further diversification and growth potential. Devonian is traded
publicly on the TSX Exchange (TSXv:GSD).

For more information, visit www.groupedevonian.com.

Forward Looking Statements

This press release contains forward-looking statements about Devonian’s
objectives, strategies and businesses that involve risks and
uncertainties. These statements are “forward-looking” because they are
based on our current expectations about the markets we operate in and on
various estimates and assumptions. Actual events or results may differ
materially from those anticipated in these forward-looking statements if
known or unknown risks affect our business, or if our estimates or
assumptions turn out to be inaccurate. Such risks and assumptions
include, but are not limited to, Devonian’s ability to develop,
manufacture, and successfully commercialize value-added pharmaceutical
and cosmeceutical products, the availability of funds and resources to
pursue R&D projects, the successful and timely completion of clinical
studies, the ability of Devonian to take advantage of business
opportunities in the pharmaceutical and cosmeceutical industries,
uncertainties related to the regulatory process and general changes in
economic conditions. You will find a more detailed assessment of the
risks that could cause actual events or results to materially differ
from our current expectations in Devonian’s prospectus dated April 21,
2017 under the heading “Risk Factors” related to Devonian’s business. As
a result, we cannot guarantee that any forward-looking statement will
materialize. We assume no obligation to update any forward-looking
statement even if new information becomes available, as a result of
future events or for any other reason, unless required by applicable
securities laws and regulations.

Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.

Contacts

Dr André P. Boulet, PhD
President and Chief Executive Officer
Devonian
Health Group Inc.
Telephone: (514) 248-7509
Email: [email protected]m